Omega-3 for PCOS: Dose, EPA vs DHA, and What Changed in Trials

Does omega-3 actually help PCOS?

Eleven randomized trials in 816 women with PCOS found that omega-3 supplementation cut HOMA-IR by 0.45 and waist circumference by 2.76 cm compared with placebo — but only with more than eight weeks of continuous use, and with no measurable change in body weight or BMI itself. That is a real, replicated metabolic effect. It is also a modest one, and it is not a weight-loss effect, whatever the marketing around fish oil implies.

A broader 2022 review of the field, covering 21 trials published between 2009 and 2019, found the same pattern: consistent improvement in insulin resistance, triglycerides, total cholesterol, and HDL, with promising but inconsistent effects on inflammatory markers like C-reactive protein, and almost nothing on anthropometric measures. Omega-3 is one entry on this site’s ranked list of PCOS supplements — a real, if moderate, metabolic option, not a weight-management tool.

EPA vs DHA: does the ratio matter for PCOS?

No published PCOS trial has directly compared an EPA-dominant formula against a DHA-dominant one, so the honest answer is that nobody has tested which ratio works better in this population. Every trial behind the numbers on this page used a combined EPA-plus-DHA fish oil, not an isolated form. The randomized fertility trial discussed below, for example, used capsules containing 360 mg EPA and 240 mg DHA per dose — a roughly 3:2 EPA-to-DHA ratio, not a pure single fatty acid.

That gap matters because EPA and DHA are not interchangeable in the rest of the nutrition literature — EPA is more associated with the anti-inflammatory pathway that PCOS trials are usually measuring, while DHA is more structurally important elsewhere in the body. Until a PCOS trial isolates one from the other, the only defensible position is to match the combined-dose range that has actually been tested, not to chase a specific ratio a product label promises.

What is the right omega-3 dosage for PCOS?

PCOS trials that produced a measurable metabolic change most commonly used at least 1,000 mg of combined EPA and DHA daily, and the trial with the strongest single-study result used 1,800 mg daily — that is what trials in this area have typically given participants, not a threshold below which omega-3 has been shown to stop working. The 2023 meta-analysis behind the HOMA-IR and waist-circumference numbers ran separate subgroup analyses for dose and for duration, and its own conclusion was that PCOS patients should take omega-3 for more than 8 weeks “regardless of the source and the dosage” — duration, not milligrams, is the variable its own data says matters.

Match the milligram figure on a supplement label to combined EPA plus DHA, not to total fish-oil weight — a 1,000 mg fish oil capsule commonly contains only 300–500 mg of actual EPA and DHA combined, which means matching the trial dose can take two or three capsules of a typical over-the-counter product, not one.

Can fish oil improve fertility and ovulation with PCOS?

In a randomized trial of 34 women with PCOS-related anovulatory infertility undergoing ovulation induction with clomiphene citrate, adding 1,800 mg of fish oil daily raised the clinical pregnancy rate to 26.7% of treatment cycles versus 13.3% with placebo, over a maximum of two cycles. Among the overweight and obese participants specifically, the gap was larger and reached statistical significance: 29.6% versus 5.3%.

That is a genuinely promising number, and it is also a small trial — 34 women, 60 total treatment cycles — that has not yet been replicated at scale. It supports omega-3 as a reasonable adjunct to discuss alongside clomiphene or letrozole for ovulation induction, not as a standalone fertility treatment or a substitute for a fertility work-up.

What changed in the omega-3 evidence over time?

Early omega-3 trials in PCOS, run mostly through the 2010s, were small, single-site, and used doses ranging anywhere from 500 mg to 4 g daily, which made the field’s early “may help with inflammation” language genuinely fair — there was no pooled number yet, just scattered signals pointing in a similar direction. The 2022 review changed that by collecting 21 trials in one place and showing the direction was at least consistent, even without a single pooled effect size. The 2023 meta-analysis went a step further and produced the actual numbers this page leads with — HOMA-IR −0.45, waist −2.76 cm — turning “may help” into a specific, citable figure for the first time.

That tightening also matters for a reason this site treats as non-negotiable: not every individual trial that turns up first in a search is reliable evidence. This page deliberately excludes at least one frequently cited PCOS fish-oil study — a small gene-expression trial whose journal issued a formal expression of concern after publication — and builds its numbers instead from the pooled meta-analyses and the single named randomized fertility trial above, each checked directly against the PubMed record rather than taken from a citation list.

Who omega-3 will not help

Omega-3 did not change body weight or BMI in any of the eleven pooled PCOS trials behind Table 1, so it is the wrong choice if weight change is specifically what you are trying to achieve — none of the mechanisms driving PCOS weight gain are ones omega-3 has been shown to move. It also has not been tested against a metformin-level insulin resistance effect, has only one small fertility trial behind it rather than a body of replicated evidence, and carries a genuine bleeding-risk interaction at high doses for anyone on an anticoagulant or already scheduled for surgery. For a supplement with a larger insulin-resistance trial base, CoQ10’s nine pooled trials are worth comparing against omega-3’s more modest numbers.

What to look for in a fish oil supplement

Trial-matching dose is the first filter: look for a label that states EPA and DHA content separately and totals 1,000–1,800 mg combined, not a product that lists “1,000 mg fish oil” with the actual omega-3 content buried in smaller print or omitted. Third-party testing (USP, NSF, or IFOS) matters more for fish oil than for most supplements, because oxidation and heavy-metal contamination are documented, verifiable problems in this specific product category — a rancid or under-dosed capsule will not reproduce anything in Table 1. Algae-based omega-3 is a legitimate EPA-and-DHA source for anyone avoiding fish, though no PCOS trial has tested an algae-derived formula specifically; the fish-oil trials above are what the numbers on this page are based on. See the rest of the supplements and medications section for how omega-3 compares against zinc’s mechanistic-only evidence and the rest of the field.

Affiliate disclosure: some links to products discussed elsewhere on this site are affiliate links, meaning we may earn a commission if you buy through them, at no extra cost to you. That does not change the dose or evidence standard described here.

You may see PCOS referred to as polyendocrine metabolic ovarian syndrome (PMOS) after a 2026 global consensus of more than 50 organisations renamed it. Nothing about the omega-3 trial evidence above changed with the name — this article uses PCOS because that is still what people search.

Common questions

Curious which supplements actually match your pattern of PCOS? The full ranked comparison sorts the evidence before you add omega-3 or anything else to your routine.